|
|
U.S. Anticoagulant MarketPublished by: Frost & Sullivan Published: Apr. 25, 2006 Table of Contents1. Executive Summary 2. Total Market 3. Warfarin Market 4. Heparins Market 5. Direct Thrombin Inhibitors Market 6. Synthetic Pentasaccharides Market 7. Emerging Anticoagulant Market 8. Appendix AbstractResearch OverviewThis Frost & Sullivan research service entitled The U.S. Anticoagulant Market provides an analysis of the following areas: warfarin, heparins, direct thrombin inhibitors, synthetic pentasaccharides, and emerging new mechanism anticoagulants. Major trends and technologies are discussed as well as revenue forecasts, market shares and product pipeline overviews. The study also highlights key industry challenges, and market drivers and restraints that are expected to impact the market. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: By End-use Segment:
New Superior Clinical Trial Results Drive Revenues In order to drive product penetration, pharmaceutical companies are forced to invest heavily in large Phase III/IV clinical trials in order to obtain the data necessary to increase product sales and expand the labels of existing products, as well as provide data to effectively execute new product launches. Furthermore, the lack of blockbuster drugs in the market challenges overall top line revenue growth, and forces the industry to focus on improving existing treatment regimens in order to increase revenues. This is crucial, since anticoagulation products still face problems related to adverse side effects, dosing, and monitoring issues that burden patients and physicians, and limit treatment effectiveness. Numerous promising compounds that show lower bleed risk, superior results in net clinical outcome endpoints, as well as beneficial findings in terms of new approaches to treatment are already under clinical development. "New data not only serves as a key differentiating factor, but also allows for the potential replacement of long-used products such as warfarin and unfractionated heparin, as companies constantly seek to enhance revenue from areas that currently utilize generics," explains the analyst of this research service. "The largest revenue opportunity for the industry is in the introduction of improved products that can be used on an outpatient basis." Product Safety and Ease of Administration Prove to be Key Competitive Factors Product safety and efficacy in terms of lowering the risk of bleeding, obtaining the desired effect, and reducing mortality rates are vital to the success of an anticoagulant product. Ease of administration is another important competitive factor, particularly in outpatient areas that require longer terms of treatment such as stroke prevention in patients with atrial fibrillation. "If a product puts the patient at greater risk due to an adverse safety profile, it leaves the door open for new products to come along and move in based on superior trial data," says the analyst. "In addition, the ability to show cost savings in the hospital is also seen as a positive for products in the space." Novel oral products with higher brand pricing and superior profiles over warfarin are expected to penetrate the outpatient setting and create new revenue opportunities. In addition to ease of administration, dosing of the product is equally crucial. There is a huge demand for anticoagulant products that have a predictable dose response and do not require monitoring in order to determine a patient’s treatment dose. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||